SamirSunilParekhMD

Hematologic Oncology

Associate Professor, Hematology/Oncology and Oncological Sciences, Icahn School of Medicine at Mount Sinai

Overview of Dr. Parekh

Dr. Samir Parekh is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from KJ Somaiya Medical College and has been in practice 18 years. Dr. Parekh accepts several types of health insurance, listed below. He is one of 187 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
10 E 102nd St
New York, NY 10029
Book by Phone+1(415) 877-1878

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2002 - 2005
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1999 - 2002
KJ Somaiya Medical CollegeClass of 1999

Certifications & Licensure

NJ State Medical License 2024 - 2025
NY State Medical License 2005 - 2025
IL State Medical License 1999 - 2005
American Board of Internal Medicine Hematology

Clinical Trials

Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia Start of enrollment: 2005 Oct 01
Unknown status
Phase 1, Phase 2
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia Start of enrollment: 2006 Nov 22
Active, not recruiting
Phase 1, Phase 2
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study) Start of enrollment: 2008 Apr 01
Completed
Phase 3
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Jul 09
Completed
Phase 2
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2009 Aug 01
Completed
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2012 Feb 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
Santiago Thibaud, Ryan L Subaran, Scott Newman, Alessandro Lagana, David T Melnekoff
Blood Cancer Discovery. 2024-11-01
2 citations
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Mitchell R Smith, Opeyemi A Jegede, Peter Martin, Brian G Till, Samir S Parekh
Blood. 2024-09-05
1 citations
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations.
Fabiana Perna, Samir Parekh, Caroline Diorio, Melody Smith, Marion Subklewe
Blood Advances. 2024-08-27

Abstracts/Posters

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myelo...
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Targeting Hypersumoylation in Mantle Cell Lymphoma
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
Samir Parekh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development of a Neoantigen Prediction Tool for Patient Stratification in Immuno-Oncology Trials
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Inherited Changes in BRCA Genes Linked to Increased Risk of Multiple MyelomaSeptember 17th, 2024
BostonGene and Mount Sinai to Collaborate on a Prospective Precision Medicine Study of Patients with Multiple MyelomaSeptember 4th, 2024
Charting the Course: Sequencing Immunotherapy for Multiple MyelomaJune 1st, 2024
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment